AbbVie’s Mavyret Approved for Hep C in Pediatric and Adolescent Patients
US Cancer Death Rate Drops 27% in 25 Years
Περισσότερα από 2,3 εκατ. ευρώ η συμβολή της Gilead για την ηπατίτιδα
As AbbVie Inc. continues to report Humira growth and investors continue to worry about biosimilar competition, the Chicago-area pharma offered a surprise when it presented its second quarter earnings: a better-than-expected performance for … Continue Reading AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Gilead Sciences, Inc. may be down, but at least one Jefferies analyst, Michael Yee, thinks the company is poised for a turnaround. For the first quarter, Gilead reported total revenues for the first quarter of $5.088 billion, compared to the … Continue Reading Is Gilead Poised for a Comeback?